Search Result

Results for "

solid malignancies

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Anaplastic lymphoma kinase (ALK) (1) Apoptosis (7) Aurora Kinase (1) Caspase (1) CCR (1) CD28 (1) CD47 (2) CD73 (1) Drug Metabolite (1) Epigenetic Reader Domain (2) FAK (1) FLT3 (1) HDAC (6) Histone Methyltransferase (1) IGF-1R (1) Insulin Receptor (1) Interleukin Related (1) JAK (1) LAG-3 (1) Orexin Receptor (OX Receptor) (1) PD-1/PD-L1 (2) Phosphatase (1) Platelet-activating Factor Receptor (PAFR) (1) PPAR (1) PROTACs (2) ROS Kinase (1) SHP2 (1) STAT (1) TNF Receptor (4) Transmembrane Glycoprotein (2) γ-secretase (2)
By Research Areas:	Cancer (32) Endocrinology (1) Inflammation/Immunology (4) Metabolic Disease (4) Neurological Disease (3)

By Targets:

Anaplastic lymphoma kinase (ALK) (1)

Apoptosis (7)

Aurora Kinase (1)

Caspase (1)

CCR (1)

CD28 (1)

CD47 (2)

CD73 (1)

Drug Metabolite (1)

Epigenetic Reader Domain (2)

FAK (1)

FLT3 (1)

HDAC (6)

Histone Methyltransferase (1)

IGF-1R (1)

Insulin Receptor (1)

Interleukin Related (1)

JAK (1)

LAG-3 (1)

Orexin Receptor (OX Receptor) (1)

PD-1/PD-L1 (2)

Phosphatase (1)

Platelet-activating Factor Receptor (PAFR) (1)

PPAR (1)

PROTACs (2)

ROS Kinase (1)

SHP2 (1)

STAT (1)

TNF Receptor (4)

Transmembrane Glycoprotein (2)

γ-secretase (2)

By Research Areas:

Cancer (32)

Endocrinology (1)

Inflammation/Immunology (4)

Metabolic Disease (4)

Neurological Disease (3)

Inhibitors & Agonists

Inhibitory Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99475

Betifisolimab MSB-2311	PD-1/PD-L1	Cancer
Betifisolimab (MSB-2311) is a humanized monoclonal antibody directed against the immunosuppressive ligand PD-L1. Betifisolimab has the potential for advanced solid tumors and hematological malignancies research .

HY-P991427

NP137	Apoptosis	Cancer
NP137 is a human IgG1 monoclonal antibody (mAb) targeting Netrin-1. NP137 inhibits the binding of netrin-1 to its receptor UNC5H2 (IC₅₀: 0.5 nM). NP137 activates caspase 3 to induce apoptosis. NP137 can be used in solid tumors and hematologic malignancies research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P99172

CC-90002	CD47 Interleukin Related	Cancer
CC-90002 is a humanized anti-CD47 monoclonal antibody (mAb). CC-90002 has a high affinity for binding to CD47 with a subnanomolar K_d value. CC-90002 can be used for the research of hematologic malignancies and solid tumors .

HY-145804

Palacaparib 1 Publications Verification AZD-9574	PPAR	Neurological Disease Cancer
AZD-9574 is a potent and brain penetrant PARP1 inhibitor and shows >8000-fold selectivity for PARP1 compared to PARP2/3/5a/6. AZD-9574 acts by selectively inhibiting and trapping PARP1 at the sites of SSBs. AZD-9574 is an anti-cancer agent and can be used for HRD ⁺?breast cancer and advanced solid malignancies research .

HY-156602

Bocodepsin OKI-179	HDAC	Cancer
Bocodepsin (OKI-179) is an orally active and selective HDAC inhibitor, with antitumor activity. Bocodepsin can be used for suppression on solid tumor and hematologic malignancies .

HY-P991612

S095024 Sym024	CD73	Inflammation/Immunology Cancer
S095024 is a humanized IgG1 monoclonal antibody inhibitor targeting CD73. S095024 can be used to study acute respiratory distress syndrome (ARDS), non-small cell lung cancer (NSCLC) and advanced solid tumor malignancies .

HY-P991151

Opamtistomig	PD-1/PD-L1 TNF Receptor	Cancer
Opamtistomig is a humanized immunoglobulin (H-γ1-scFv-L-κ) dimer monoclonal antibody targeting human programmed death ligand 1 (PD-L1), CD274 and tumor necrosis factor receptor superfamily member 9 (TNFRSF9). Opamtistomig is promising for research of various solid tumors and hematological malignancies .

HY-149283

JAK/HDAC-IN-2	JAK HDAC Apoptosis	Cancer
JAK/HDAC-IN-2 is a potent 2-amino-4-phenylaminopyrimidine JAK/HDAC dual-target inhibitor. JAK/HDAC-IN-2 potently inhibits HDAC3/6 and JAK1/2 at nanomolar levels. JAK/HDAC-IN-2 has proapoptotic activity and inhibits histone deacetylation and STAT3 phosphorylation. JAK/HDAC-IN-2 presents remarkable antiproliferative activity in both hematological malignancies and solid cancers .

HY-156602A

Bocodepsin hydrochloride OKI-179 hydrochloride	HDAC	Cancer
Bocodepsin hydrochloride (OKI-179) is an orally active and selective HDAC inhibitor, with antitumor activity. Bocodepsin hydrochloride can be used for suppression on solid tumor and hematologic malignancies .

HY-106833A

SDZ-62-434	Platelet-activating Factor Receptor (PAFR)	Metabolic Disease
SDZ-62-434 is a platelet-activating factor (PAF) antagonist. SDZ-62-434 has antiproliferative activity in human solid and haematological malignancies .

HY-W741181

Epirubicinol Epidoxorubicinol; 4'-Epidoxorubicinol	Drug Metabolite	Cancer
Epirubicinol is a 13-dihydro metabolite of Epirubicin (HY-13624). Epirubicin has activity similar to Doxorubicin (HY-15142A) in a variety of solid neoplasms and haematologic malignancies .

HY-P991135

Enzelkitug	CCR	Cancer
Enzelkitug is a humanized immunoglobulin G1-κ monoclonal antibody targeting the human C-C motif chemokine receptor 8 (CCR8). Enzelkitug is promising for research of various solid tumors and hematological malignancies .

HY-136173

Batoprotafib 5 Publications Verification TNO155	SHP2 Phosphatase	Cancer
Batoprotafib (TNO155) is a potent selective and orally active allosteric inhibitor of wild-type SHP2 (IC₅₀=0.011 µM). Batoprotafib has the potential for the study of RTK-dependent malignancies, especially advanced solid tumors .

HY-109174

Fosciclopirox CPX-POM	γ-secretase	Metabolic Disease Cancer
Fosciclopirox (CPX-POM) suppresses growth of urothelial cancer by targeting the γ-secretase complex. Fosciclopirox selectively delivers the active metabolite, Ciclopirox (CPX), to the entire urinary tract. Ciclopirox has anticancer activity in a number of solid and hematologic malignancies .

HY-P99057

Varlilumab CDX-1127	TNF Receptor Transmembrane Glycoprotein	Inflammation/Immunology Cancer
Varlilumab (CDX-1127) is an agonist anti-CD27 monoclonal antibody. Varlilumab can promote T cell expansion and activate the immune response. Varlilumab has anti-tumor activity and can be used in the research of hematological malignancies and solid tumors .

HY-109174A

Fosciclopirox disodium CPX-POM disodium	γ-secretase	Metabolic Disease Cancer
Fosciclopirox disodium suppresses growth of urothelial cancer by targeting the γ-secretase complex. Fosciclopirox disodium selectively delivers the active metabolite, Ciclopirox (HY-B0450), to the entire urinary tract. Ciclopirox has anticancer activity in a number of solid and hematologic malignancies .

HY-P99249

Vonlerolizumab Pogalizumab; MOXR 0916	Orexin Receptor (OX Receptor)	Cancer
Vonlerolizumab (Pogalizumab; MOXR 0916) is a humanized IgG1 monoclonal antibody targeting OX40 (CD134). Pogalizumab partially blocks the interaction between OX40 and its natural ligand OX40L upon binding, thereby activating the NF-κB signaling pathway. Pogalizumab enhances T cell activation and proliferation and has shown antitumor activity in mouse models .

HY-173266

TO-1187	PROTACs HDAC	Neurological Disease Cancer
TO-1187 is a selective HDAC6 PROTAC degrader (DC₅₀: 5.81 nM). TO-1187 promotes the ubiquitination and degradation of HDAC6 and can be used in the study of hematological malignancies and solid tumors (Pink: HDAC6 ligand (HY-173386); Blue: CRBN ligase ligand (HY-41547); Black: linker (HY-140212)) .

HY-P99057A

Varlilumab (anti-CD27) CDX-1127 (anti-CD27)	TNF Receptor Transmembrane Glycoprotein	Inflammation/Immunology Cancer
Varlilumab (CDX-1127) (anti-CD27) is an agonist anti-CD27 monoclonal antibody. Varlilumab (anti-CD27) can promote T cell expansion and activate the immune response. Varlilumab (anti-CD27) has anti-tumor activity and can be used in the research of hematological malignancies and solid tumors .

HY-173266A

TO-1187 TFA	PROTACs HDAC	Neurological Disease Cancer
TO-1187 TFA is a selective HDAC6 PROTAC degrader (DC₅₀: 5.81 nM). TO-1187 TFA promotes the ubiquitination and degradation of HDAC6 and can be used in the study of hematological malignancies and solid tumors (Pink: HDAC6 ligand (HY-173386); Blue: CRBN ligase ligand (HY-41547); Black: linker (HY-140212)) .

HY-P990033

Anzurstobart CC-95251; BMS-986351	CD47	Cancer
Anzurstobart (CC-95251; BMS-986351) is a high-affinity, fully human monoclonal anti-SIRPα antibody that blocks the binding of CD47 to SIRPα. Anzurstobart enhances macrophage phagocytic activity against DLBCL cell lines in co-culture models when combined with the antibody Rituximab (HY-P9913). Anzurstobart has the potential for solid and hematologic malignancies research .

HY-170226

BET-IN-28	Epigenetic Reader Domain	Cancer
BET-IN-28 (Compound 44) is a highly potent inhibitor of bromodomain and extra-terminal domain (BET), with an IC₅₀ value of 4.47 nM against BRD4-BD1. BET-IN-28 blocks the interaction between BET proteins and N-acetylated lysine residues on histone tails, down-regulates certain genes. BET-IN-28 can be used for hematological malignancies and solid tumors study .

HY-178140

STAT3-IN-47	STAT	Cancer
STAT3-IN-47 is an orally active STAT3 inhibitor. STAT3-IN-47 exhibits broad-spectrum anti-tumor activity against HeLa, HepG2, U87, and LN229 cells. STAT3-IN-47 suppresses STAT3 activation in vitro. STAT3-IN-47 can be used for the study of solid tumors, especially central nervous system (CNS) malignancies and hepatocellular carcinoma .

HY-155163

APG-2449	Anaplastic lymphoma kinase (ALK) ROS Kinase FAK Apoptosis	Cancer
APG-2449 is an orally active inhibitor for BCL-2 and multikinase (ALK/FAK/ROS1) with potent antitumor activities. APG-2449 reduces cell viability and enhances apoptosis in acute myeloid leukemia cells in vitro. APG-2449 decreases activation of FAK and its downstream effectors. APG-2449 can be studied in research for mesothelioma tumor, non-small cell lung cancer, ovarian cancer, hematologic and solid malignancies .

HY-P99934

Eftozanermin alfa 1 Publications Verification ABBV-621	Apoptosis Caspase TNF Receptor	Cancer
Eftozanermin alfa (ABBV-621) is a tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAIL-R) agonist. Eftozanermin alfa is a fusion protein consisting of a mutant immunoglobulin G1-Fc linked to 2 single-chain trimers of TRAIL. Eftozanermin alfa induces apoptosis in tumor cells by activation of death receptors (DR4 receptor and DR5 receptor) with K_ds of 780 nM and 635 nM. Eftozanermin alfa can be used for the research of multiple solid and heme malignancies .

HY-158618

Aurora kinase inhibitor-14	Aurora Kinase Apoptosis	Cancer
Aurora kinase inhibitor-14 (Compound 79) is an orally active and highly selective inhibitor of Aurora kinases with IC₅₀ values of 0.5 nM and 1.2 nM for Aurora A and Aurora B, respectively. Aurora kinase inhibitor-14 binds to the ATP-binding site of Aurora kinases to block chromosome segregation during mitosis and induce apoptosis in tumor cells. Aurora kinase inhibitor-14 is promising for research of various solid tumors and hematological malignancies, such as non-small cell lung cancer, breast cancer, and acute myeloid leukemia .

HY-P99027

Ieramilimab LAG525; IMP701; Hu5A8	LAG-3	Cancer
Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules. Ieramilimab restores T-cell and NK-cell-mediated antileukemic immunity by reducing exhaustion and augmenting cytokine output and cytotoxicity. Ieramilimab increases the infiltration of cytotoxic T lymphocytes and reduces baseline densities of regulatory T cells (Tregs) and ADAM10-expressing tumor cells. Ieramilimab can be used for the study of various malignancies including melanoma, RCC, and advanced solid tumors .

HY-169076

FLT3/HDAC-IN-1	FLT3 HDAC Apoptosis	Cancer
FLT3/HDAC-IN-1 is a dual inhibitor of FLT3/HDAC, with IC₅₀ values of 30.4, 52.4, and 14.7 nM for FLT3, HDAC1, and HDAC3, respectively. FLT3/HDAC-IN-1 can induce apoptosis in MV-4-11 cells and has anti-proliferative effects on FLT3 mutant-transformed BaF3 cells. FLT3/HDAC-IN-1 is being researched for its potential in treating hard-to-treat solid tumors and hematological malignancies .

HY-161670

NSD2-PWWP1 ligand 1	Histone Methyltransferase	Cancer
NSD2-PWWP1 ligand 1 (compound 34) is a small molecule ligand targeting the NSD2-PWWP1 domain (pIC50: 8.2). NSD2 is a large multidomain protein with histone writer and histone reader functions. Dysregulation of the levels of histone methyltransferase nuclear receptor binding SET domain 2 (NSD2) may lead to a variety of hematological and solid malignancies. NSD2-PWWP1 ligand 1 binds to NSD2, reducing its enzymatic activity and inhibiting tumorigenesis .

HY-P9986

Tiragolumab MTIG-7192A; RG-6058	CD28	Cancer
Tiragolumab is an immune checkpoint inhibitor binding to the T-cell immunoglobulin and ITIM domain (TIGIT). Tiragolumab in combination with Atezolizumab (HY-P9904) and Bevacizumab (HY-P9906) has benefit in unresectable hepatocellular carcinoma. Tiragolumab can be used to study non-small cell lung cancer (NSCLC) and melanoma .

HY-150105

Icovamenib BMF-219; Menin-MLL inhibitor 21	Epigenetic Reader Domain	Metabolic Disease Inflammation/Immunology Cancer
Icovamenib (BMF-219) is a selective, orally active, irreversible Menin inhibitor. Icovamenib forms a stable and irreversible covalent bond with Menin. Icovamenib promotes selective and controlled proliferation of beta cells and improvement of beta cell function in ex vivo human islet cultures. Icovamenib enhances glycemic control in animal diabetic models. Icovamenib induces a dose-dependent enhancement in insulin secretion potentiated by the GLP-1 RA. Icovamenib can be used for the study of multiple hematologic malignancies, solid tumors, and diabetes mellitus, such as diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM) and chronic lymphocytic leukemia and type 2 diabetes .

HY-10252

NVP-ADW742 3 Publications Verification ADW742; GSK 552602A; ADW	IGF-1R Insulin Receptor Apoptosis	Endocrinology Cancer
NVP-ADW742 (ADW742) is an orally active, selective IGF-1R tyrosine kinase inhibitor with an IC₅₀ of 0.17 μM. NVP-ADW742 inhibits insulin receptor (InsR) with an IC₅₀ of 2.8 μM. NVP-ADW742 induces pleiotropic antiproliferative/proapoptotic biologic sequelae in tumor cells .

Cat. No.	Product Name	Target	Research Area